Source: Web Search Revision Year: 2013 Publisher: Les Laboratoires Servier
Pharmacotherapeutic class: DOPAMINERGIC AGONISTS
ATC code: N04BC08
Piribedil: dopaminergic agonist (stimulates dopamine receptors and the cerebral dopaminergic pathways).
In humans, the mechanism of action is demonstrated by the clinical pharmacology studies:
In addition, piribedil results in an increase in femoral blood flow (the existence of dopaminergic receptors in the femoral vascular bed explains the action of piribedil on peripheral circulation).
Piribedil is absorbed rapidly.
The maximum concentration is reached one hour after oral administration of piribedil. Plasma elimination is biphasic and is composed of a first phase characterised by a half-life of 1.7 hours and a second, slower phase characterised by a half-life of 6.9 hours.
Metabolism of piribedil is intense, with two main metabolites: (a hydroxylated derivative and a dihydroxylated derivative).
Piribedil is excreted essentially in the urine: 68% of the piribedil absorbed is excreted by the renal route in the form of metabolites and 25% is excreted in bile.
The tablet containing 50 mg of sustained-release piribedil allows in vivo gradual absorption and release of the active ingredient.
The kinetic studies conducted in humans show extension of the therapeutic coverage which exceeds each 24 hour period.
Urinary excretion is approximately 50% at the 24th hour and is total at the 48th hour.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
